BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.850
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -95.73% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for BioXcel Therapeutics stock have an average target of 42.6, with a low estimate of 4.00 and a high estimate of 80. The average target predicts an increase of 2,202.70% from the current stock price of 1.85.
Analyst Consensus: Buy
* Price targets were last updated on Mar 19, 2025.
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +3,413.51% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $48 | Strong Buy | Maintains | $80 → $48 | +2,494.59% | Jan 30, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $112 → $4 | Strong Buy → Sell | Downgrades | $112 → $4 | +116.22% | Jan 7, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $112 → $80 | Strong Buy | Maintains | $112 → $80 | +4,224.32% | Jan 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $112 → $80 | Strong Buy | Maintains | $112 → $80 | +4,224.32% | Oct 21, 2024 |
Financial Forecast
Revenue This Year
3.20M
from 2.27M
Increased by 41.00%
Revenue Next Year
9.50M
from 3.20M
Increased by 197.21%
EPS This Year
-20.07
from -23.51
EPS Next Year
-14.29
from -20.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.0M | 24.5M | 114.9M | ||
| Avg | 3.2M | 9.5M | 49.3M | ||
| Low | 1.5M | 3.1M | 10.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 122.4% | 666.7% | 1,109.7% | ||
| Avg | 41.0% | 197.2% | 419.2% | ||
| Low | -35.1% | -1.8% | 9.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -8.23 | -8.40 | -2.52 | ||
| Avg | -20.07 | -14.29 | -6.11 | ||
| Low | -31.93 | -23.28 | -8.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.